Revolutionizing cell therapy for inflammatory diseases via neonatal cardiac progenitor cells and their secretomes Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs. The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Anti-Infectives, Drug Discovery, Antibiotics, and Microbiology

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biomade Peptides We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering next-generation antibody therapies with AI and computational protein design Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. Archon …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming protein biologics with groundbreaking high-throughput protein engineering. Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biology and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, …

142 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer VerImmune is advancing Anti-tumor Immune Redirection (AIR): A Breakthrough Therapy that Redirects Pre-Existing Immune Memory from Childhood Vaccination or Infection to Fight Cancer

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies. GRO Biosciences transforms protein therapeutics with new amino acid building blocks to treat incurable diseases. Protein therapeutics, Biologics, and Genomic recoding

99 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Ferring Company working to harness the power of the human microbiome to address unmet medical needs. Rebiotix Inc, part of the Ferring Pharmaceuticals Group, is a clinical-stage biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome. Our highly skilled and dynamic team is based out of Roseville, Minnesota. Please feel free to contact us through our website at www.rebiotix.com. Biotechnology, Microbiome, Drug Development, Medicine, Clinical Trials, Regulatory Innovation, Patient Support, Internal Medicine, Manufacturing, Infectious Disease, Gastroenterology, Emerging Diseases, and Novel Technology

64 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Customized phage therapies to eradicate harmful bacteria in chronic diseases BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. Microbiome, Biotechnology, Drug Discovery, Phage Therapies, and Pharma

108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to discover, develop and deliver next generation cancer therapies. G1 Therapeutics, Inc. is a wholly owned subsidiary of Pharmacosmos. Cancer / Oncology, Drug Discovery and Development, and Biotechnology

160 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Automated protein crystallography for faster new structures and expert small molecule screening. All our services include access to fully automated, remote-controlled protein-to-structure pipelines based on the innovative technologies CrystalDirectTM and CRIMS developed at EMBL.

55 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

LinKinVax aims at creating a universal, safe, enduring, vaccines platform against multiple pathogens. We are a clinical stage Biotech Spin-off of the Vaccine Research Institute in France with a unique "DC targeting" platform covering infectious desaeses and oncology.

161 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First in class small molecules pushing cancer cells to burn out BiPER Therapeutics is developing a first-in-class pipeline of therapeutics overstressing cells to cure patients. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next generation bioproduction platform Kyron.bio is revolutionising the way we make our therapeutic drugs. Our novel engineering strategy allows us to precisely control the glycosylation pattern on the surface of a biologic in order to develop the next generation of medicines. This unique approach enables us to sculpt biologics based on the sugars that are attached to the surface, helping to make therapeutics safer and more effective. Our work at Kyron.Bio is opening up a new era of biologics engineering – one with the power to create positive health outcomes for patients whose needs are currently unserved by the pharmaceutical …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies. Single molecule analysis, RNA Drug Discovery, Protein-protein Interaction Analysis, Biophysics, Drug Discovery, Compound Screening, biomolecular interactions, and interactomics

159 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

3D printed personalized medicines MB Therapeutics is a pharmaceutical company that offer patient centric solutions to Develop and produce personalized medicines. MB Therapeutics solution is powered by 3D printing, allowing dosage, shape and API customization in GMP environement Pharmaceutical development, Pharmaceutical 3D printing, and Personalized medicines

63 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

A nature-inspired solution to trap pathogens @AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases. Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens. GlycoFlu, our first drug-candidate validated at the …

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Smartox Biotechnology is specialized in peptide research and manufacturing Smartox Biotechnology is specialized in peptide research and engineering. Peptide synthesis, physiology, pharmacology, neuroscience, ion channel research, toxin, venomous animals, and screening library

336 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Machine Bio is a biotech company offering unique protein synthesis and purification solutions. Machine Bio is an early stage biotechnology company developing a novel, proprietary protein synthesis platform that can produce pure protein from a DNA template in a easy-to-use, single-step, 4 hour process. Proteins are broadly used in many industries and Machine Bio’s platform has a range of possible applications across drug discovery and development, synthetic biology research, industrial enzyme optimization, and commercial therapeutic manufacturing. Protein Synthesis, Protein Purification, Contract Protein Expression, R&D, Startup, Cell-Free Systems, and Supported Lipid Bilayer

71 similar entities Type: Startup Activities: deeptech biotech manufacturing Technologies: Synthetic Biology

Developing Tomorrow's Antibacterials Antabio is a privately-held clinical-stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments for drug-resistant infections due to CDC and WHO critical priority pathogens. Please visit www.antabio.com and follow us on Twitter @antabio Antibacterial drug discovery, Drug development, and Antibiotic Adjuvant

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to cure genetic diseases At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advanced molecular analysis technologies to harness the power of the microbiota. To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection.

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Syndivia is committed to enhancing treatment options for cancer patients with solid tumors by leveraging the distinctive properties of targeted DAR1 antibody-drug conjugates, which offer improved tumor penetration, stability, and efficacy. Drug development, Biotechnology, Pharmaceuticals, Antibody-drug conjugates, DAR1 ADC, and ADC

156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Expertise in protein engineering | in silico & in vitro antibody discovery platform We work in partnership with technology platforms, pharmaceutical companies, and academic research groups to create next generation cell and molecular therapies. We integrate novel technologies into a synthetic antibody platform to provide the most advanced discovery engine possible.

259 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

The Protein Design Company (TM) - new proteins and biochemistry for the production of valuable sustainable molecules Arzeda, The Protein Design CompanyTM, is a synthetic biology company that creates novel proteins, enzymes and specialty chemical products that compete on performance, cost and sustainability. Partnering with Fortune 500 companies, Arzeda has developed a portfolio of enzymes and specialty chemicals for polymers, pharmaceuticals, industrial chemicals and other advanced applications. More information at www.arzeda.com. Synthetic Biology, Bio-based Chemicals, and Protein Design

95 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Superior and effective microbiome therapeutics CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Utilizing unique protein superglue technology to develop vaccines against infectious disease and cancer worldwide SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year. Vaccine Development

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Changing the way we see the gut Motilent is a technology SME focused on delivering innovative services for the quantitative investigation of the gut. Motilent champions the use of novel MRI post-processing software as a cheaper and safer biomarker for Gastrointestinal and Bowel Disorders, providing quantitative end points for research, drug development and clinical decision-making.

29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

From Sea to Pharmacy ManRos Therapeutics is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors for the treatment of cystic fibrosis. ManRos was founded in 2007 and is led by Dr Laurent MEIJER, Chairman and CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de Lavenne, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Drug Development, Cystic Fibrosis, and Biotechnology

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the power of NIK to transform the future of cancer and autoimmune disease treatment Nikaia Pharmaceuticals, an innovative company dedicated to the discovery and development of cutting-edge therapeutic solutions to improve patients' lives. 🔬💊 Our mission is to push the boundaries of science to deliver novel and effective treatments, focusing on the NIK protein (NF-κB-inducing kinase) and developing molecules capable of blocking its action.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

goes FAR BEYOND (Fighting Antimicrobial Resistance to the Biological EmergencY to Opportunistic and Neglected Diseases) Dimicare Biotech is a project from Université Côte d'Azur, INSERM and CNRS focused on the development of novel "precision" antimicrobial drugs to fight multidrug-resistant infections. Our main project focuses on the development of a new treatment against multidrug-resistant S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus strains). Currently, this treatment is in the early-preclinical phase where its efficacity against several clinical strains and its innocuity in Human cells has been confirmed. Dimicare Biotech is building a great team involving Microbiology Medical doctors, …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of novel distinctive small molecule therapeutics that modulate G protein-coupled receptor (GPCR) pathways. The company is developing new proprietary small molecule therapeutic candidates with the intention of developing best-in-class therapeutics for the treatment of unmet metabolic, inflammatory and fibrotic diseases, using its integrated drug discovery platform, expertise in medicinal chemistry and deep understanding of GPCR biology. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. See our social media community guidelines at https://liminalbiosciences.com/social-media-community-guidelines/

72 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Cellvax, founded in 2001, is a preclinical biotech company which provides in vitro and in vivo studies allowing accelera Cellvax, founded in 2001, is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields. Cellvax is a fast-growing technology-driven preclinical service company. Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products. Preclinical studies CRO, Animal models, Cancer, Osteoarthritis, Bio-markers, …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

375 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Small molecule GLP/GMP manufaturing Roowin is a privately owned Contract Research Organisation (CRO) headquartered at Riom, Auvergne, France. Its core business being in high value added fine chemistry, Roowin offers services in the following areas: • GMP synthesis • Clean room synthesis • Lead optimization • Scale up, process development • Custom synthesis • Analytical chemistry services We are proud to be able to accompany our customers from early drug discovery over process development to medium-scale GMP production, supporting our operations by strong analytical chemistry capabilities. GMP production, Lead Optimization, Clean room synthesis, Custom Synthesis, scale up, and process development

45 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

DNA Synthesis Uncompromised Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented Fully Enzymatic Synthesis (or FESTM), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. *Fully Enzymatic Synthesis and FES are the trademarks of …

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Proteins Structures Got Easier With Crystallophores Emerged from academic research, POLYVALAN (IBS & ENS Lyon Spin-off company) is a young innovative company founded in December 2016 dedicated to structural biology. POLYVALAN competitive edge is its unique chemical approach allowing significant gain of effectiveness, time and/or precision for protein structure determination that allows an optimal use of the existing large equipments. structural biology, protein crystallization, crystallization screening, nucleating agent, phasing agent, crystallophore, structure determination, X-ray crystallography, and drug design

59 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

From Molecules to Medicine and Beyond NMR-Bio is a CRO located in Grenoble (France), one of the most vibrant European hubs for structural biology and supplies compounds for the selective labelling of methyl groups in perdeuterated proteins. NMR-Bio also offers a broad range of services for NMR applications: - Custom labelled protein production in bacteria, cell-free system, insect cells, HEK293 and CHO cells - Solution for labelling of your biopharmaceutics especially mAbs and Fabs - High-field NMR data acquisition and analysis (e.g. quality control, spectra assignment, structure calculation, dynamic characterisation).

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Biomanufacturing services Naobios provides bioprocess development and contract manufacturing services for viral vaccines and viral vectors. The company was acquired by Clean Biologics on March 1st, 2019 and now supports clients for process development and the manufacture of preclinical and clinical batches.

159 similar entities Type: Startup Activities: manufacturing deeptech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

333 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

What You See Is What You Seq - Revolutionary cell analysis solution for fundamental, translational & pharma/biotech R&D Minos Biosciences is on the path to bridge molecular and cell biology in a manner never achieved before that will, in turn, allow scientists to uncover the full picture of cell diversity and dynamics. By combining multi-omics analysis with phenotypic analysis at cell resolution and at high throughput, Minos’ solution provides a new paradigm in cell analysis that will open up new frontiers in life science research, precision medicine and diagnostics.

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A Technology Development and Advisory Company Focused on Medical Devices/Biologics Strategic Advisory Services for both large & small medical device/biologics companies including acquisition, licensing, distribution, joint venture agreements Market, Scientific and Clinical Due Diligence Services Business development Services for venture capital, private equity, hedge funds and investment banking clients & their portfolio companies and clients Product/Device development Strategic Product Postioning including licensing, distribtution and market positioning New Company Formation

520 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

186 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Fermentation bioprocess technology Applying a mixed-culture fermentation bioprocess for the production of pharmaceuticals. Biotechnology, Pharmaceuticals, R&D, Fermentation, Glycosaminoglycans, and Heparin

77 similar entities Type: Startup Activities: biotech deeptech

Unlocking the access to innovative ingredients and APIs from cannabis, thanks to plant biotechnology. STH BIOTECH develops unique and reliable plant-biotech process to produce cannabinoids at high yield & low cost.

63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Believe in Nature, belong to Future BGene aims at developing sustainable and resilient production ways for high value added, biobased molecules. To this end, BGene develops expertise in domains such as molecular biology, microbiology, biochemistry, process engineering and computer sciences. Food and feed, pharma, cosmetics, chemistry, and environment are among the diverse markets that BGene can address thanks to the cutting-edge bioprocesses developed by BGene know-how. Strain engineering, Microorganism chromosome engineering, Synthetic Biology, Molecular Biology, Bioinformatics, Bioprocess, and Enzyme Engineering

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Bio sourced materials Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Modulating T-regulatory cells to balance immunity Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

185 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nevezyne develops her own protein expression systems and offers her expertise in the expression of recombinant proteins, for research programs, for animal health diagnosis, human Protein expression, badvirus system, protein purification, and bacterial system

108 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

European Distributor of innovative cell culture products KDBIO is distributing advanced cell culture devices used for producing monoclonal antibodies, and 3D culture plates for generating multiple spheroid replicates per well, as well as 3D culture plates with nanofiber scaffolds. G-Rex culture systems can be purchased from KDBIO in the EU. Distribution, monoclonal antibodies, 3D culture, CAR-T, and Patient-derived spheroids

54 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.

70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Founded in 1951 by pharmacists and microbiologists, biose® has 60-year experience in drug based on live bacteria, giving us a deep understanding of the entire process from discovery to commercialization. Focused on Health through microbiota and microbiome science, we use our skills for the discovery, product development, clinical studies and manufacturing of Live Biotherapeutic Products (LBPs). Our company is drug-GMP certified for the manufacturing of bacteria-based APIs, clinical and commercial products. Microbiome Therapeutics, live biotherapeutics, LBPs, and CDMO

117 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Biocatalysis from Lab to Industrial Scale Protéus is a pioneer in protein engineering technologies, with now 20 years expertise in developing tailored enzymes and scaling-up biocatalytic processes. Proteus offers: - An exclusive and diversified microorganism collection (including micro-algae and thousands of bacteria and archaebacteria extremophiles strains) - 1,000 sequenced strains, combined with data mining tools, offering a unique pool of millions enzymes - Patented directed evolution technologies (EvoSightTM & L-ShufflingTM) to optimize enzymes performances - A multidisciplinary skilled team dedicated to custom bioprocess development for client’s applications - Seqens CDMO capabilities enabling large scale biocatalytic production of chemicals & pharmaceuticals …

91 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Subsidiary of BioNTech SE, now trading as BioNTech R&D (Austria). Developing novel anti-bacterials. BioNTech R&D Austria GmbH (formerly: PhagoMed Biopharma GmbH) is a fully owned subsidiary of BioNTech. The team in Vienna focuses on developing novel anti-bacterial drugs for persistent bacterial infections. Biotech

56 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Discover your favorite frequencies to boost your drug discovery business CellSine provides devices and software that make advanced electrochemical impedance spectroscopy easily accessible to any microbiological researcher. It delivers a platform tool for a that enables a wide variety of biochemical studies. Biotechnology, Cell culture monitoring, Proteïn - Proteïn interactions, Suspension cultures, Receptor signaling, Biofilm maturation, and T lymphocyte activation

206 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

R&D stage veterinary therapeutics biotechnology company based in Cambridge, UK The PetMedix channel will soon be discontinued as we join forces with Zoetis. Follow the Zoetis channels to stay connected and for the latest updates! Biotechnology, Drug Development, Drug Discovery, Therapeutic Antibodies, Monoclonal Antibodies, Companion Animal, Veterinary Medicine, and Research and Development

62 similar entities Type: Startup Activities: pettech biotech deeptech Technologies: Synthetic Biology

Customer-centric and science-driven CDMO supporting biopharma companies from R&D to market GTP Bioways is an expert and fast-growing contract development and manufacturing organisation (CDMO) offering uniquely customised process development and manufacturing services for biologics, antibody-drug conjugates and nanodrugs. With cutting-edge facilities located in France, GTP Bioways supports biopharma companies in bringing their innovative molecules from research to clinic and market. GTP Bioways is an Olon company. Biologics, Nanodrugs, Process Development, Analytics, Biopharmaceuticals, and GMP Manufacturing

61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Chemical tools for bioconjugaison & biodrugs McSAF is a Deeptech company specialized in Bio-Organic & Bio-Conjugates Chemistry, developing innovative technologies for improved targeted therapies. Its core expertise covers Therapeutic Peptides and Proteins, Antibodies, and Drug Conjugates. The team has a strong background in synthetic selective chemistry, and a real expertise in bioconjugation, including specific designs of Antibody Drug Conjugates (ADCs) with own proprietary coupling technology. Plus, the company has now a pipeline of three products in oncology incorporating McSAF Inside technology with the ambition to bring new biodrugs on the market solving unmet medical needs. Bioconjugation, Biopharmaceuticals, Antibody Drug Conjugates, …

77 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Research company, GMP manufacturer & global supplier of live vaccines to the intensively farmed food animal industry. Bioproperties Pty Ltd is a leading Australian novel vaccine research company (Melbourne), GMP manufacturer (Sydney) and global supplier of live vaccines to the intensively farmed food animal industry.

59 similar entities Type: SMB Activities: foodtech deeptech Technologies: Synthetic Biology

Leadership in overcoming the antibiotic resistance crisis. BioVersys AG is a SIX listed (BIOV) clinical stage Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in antimicrobial resistance (AMR) and targeted microbiome modulation. With the company’s two in house technology platforms: i) TRIC and ii)Ansamycin chemistry, BioVersys develops novel, innovative antibacterial drugs, overcoming resistance and modulating the microbiome. By this means, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced research and development programmes address nosocomial …

42 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redefining microbiome-based therapeutics MRM Health NV is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.The company is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent, Belgium, and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB and has a corporate collaboration with DuPont Nutrition …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

High-Capacity Gene Therapy Vector Platform to Address Prevalent Diseases GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium. biotechnology, gene therapy, osteoarthritis, drug development, human …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redefining Synthetic Lethality beyond HRD Tessellate BIO discovers and develops novel precision oncology medicines with the mission to turn cancer patients into cancer survivors. A private preclinical stage biotechnology company, Tessellate BIO is redefining Synthetic Lethality by developing drugs that target unexplored or difficult to drug pathways beyond HRD. Headquartered in the Netherlands and with research labs at the Stevenage Bioscience Catalyst, UK, Tessellate BIO is supported by top-tier life science investors BioGeneration Ventures (BGV) and Forbion. drug discovery, precision oncology, and biotechnology

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We digitalise preclinical studies to increase welfare and research quality. TrackPaw Scientific's deep tech solution for 24/7 monitoring of early stage pharmaceutical development offers improved animal welfare together with better study outcomes. Biotechnology , Drug development, Machine learning, Artificial Intelligence, Deep tech, Preclinical research, Animal welfare, and 3R

108 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

662 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better technology for better health LimmaTech Biologics AG is a Swiss-based clinical stage biopharmaceutical company. We are advancing our proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. In addition to our proprietary research, we also develop vaccines together with GSK. vaccines, research & development, biotechnology, and antimicrobial resistance

147 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AstronauTx is tackling dementia through improving brain physiology AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease.

101 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Proteins For Sustainability Cocoon Bioscience specializes in the manufacturing of high performance growth factors and enzymes using an automated platform leveraging cocooned insects as natural, low cost bioreactors.

173 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

438 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovating a New Class of Medicines to Drug the Undruggable InFocus is a discovery-stage biotechnology company dedicated to true innovation for novel therapeutic modalities. We are integrating unique experimental technologies with a state-of-the-art algorithm-driven drug discovery platform, to develop next-generation small molecule drugs against undruggable targets at unprecedented scale.

119 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics. Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing Evogene's Computational Predictive Biology (CPB) platform.

96 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Glycoscience and microbiota research specialized company GLYcoDiag is a French research company (SME) specialized in glycosciences and microbiote services and product. Our business area covers the domains of human and animal health (biomarkers, therapeutic recombinant glycoproteins, vaccines), cosmetics (active ingredients, design and mechanisms of “glyco-actives”) and environment (biofilms, waste water). glycobiology, lectins glycoprofiling, oligosaccharides, glycoconjugates, microbiota, glycosciences, and cosmetics

65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Saving lives through affordable and efficient bacterial vaccines Our vision is to save lives with affordable and efficient vaccines against bacterial infections. At the core of our work is a platform technology that enables us to develop innovative bacterial vaccines with broad protection and high efficacy. This technology has the potential to significantly reduce or eliminate the need for antimicrobials.

Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Providing essential, standardized tools to accelerate breakthroughs in human health Microfluidics | Cytometry | Imaging Standard BioTools delivers the leading proteomic and multi-omic solutions that enable researchers to discover unique biological insights not accessible by other technologies. Mass Cytometry, Tissue Imaging, NGS Library Prep, Genotyping, Gene Expression, Copy Number Variation, Real-Time PCR, and Single-Cell Genomics

184 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Research center & amp; Health development Bionoveo offers project leaders, industrial or academic, biological, technical and methodological skills and resources necessary for the development of new therapeutic and diagnostic strategies, as well as their production processes.

283 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology

Oral small molecules for rare diseases Alesta Therapeutics is a pioneering company based in Leiden, Netherlands, dedicated to the development of first-in-class small molecules that target GCN2. Our commitment to advanced, high-quality chemistry has led us to develop a clinical candidate with an extensive pre-GLP toxicology and CMC package.

137 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

An evolution in cell line engineering. High throughput engineering of cell lines to enhance the design and manufacture of next-generation therapeutics. Gene therapy, Synthetic Biology, Genome Engineering, and Functional Genomics

171 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Aseptix Health Sciences is a global leader in next generation antimicrobials, specializing in novel and patented infection prevention products and technologies for medical, professional and consumer use. Aseptix’ sustainable antimicrobial technologies enable products to safely, effectively and quickly kill contagious pathogens and are used in a wide range of applications, industries and therapeutic areas. The Company markets its products and technologies through a combination of Aseptix branded and third party branded products, and licenses on its portfolio of patented technologies to global industry leaders in their markets. The corporate mission is to become the global alternative for user unsafe and …

65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Peptide-based therapeutics for treating peripheral pain conditions At Akasi Pharma, we are developing novel peptide-based therapeutics to treat peripheral pain conditions Peptide therapeutics and Peripheral Neuropathic Pain

141 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We turn blood stem cells into living drug factories At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

221 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Bioscibex, we are redefining bioprocessing with innovative single-use bioreactor solutions tailored for modern biologics and cell therapy manufacturing. Our mission is to empower researchers and manufacturers with tools that simplify processes, enhance scalability, and improve efficiency.

260 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Focusing on Resistance in Antibiotic Development Qpex Biopharma, Inc. a Shionogi Group Company, is a resistance-focused infectious disease company on a mission to make both a dramatic and sustainable improvement in patient care. Leveraging a multi-faceted approach and a deep understanding of drug resistance mechanisms, we are creating novel products and development. strategies that overcome multi-drug resistance. We are advancing a robust portfolio of treatments that will bring innovation to antibiotic development and deliver the right treatments to the right patients in the right settings. During the previous decade, our team brought 4 antibiotic products to regulatory approvals, with an …

12 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cell Tree Analytics, somatic mutation tracking, clonal structure quantification, check out our Cell Tree Rings study here https://www.biorxiv.org/content/10.1101/2022.12.14.520419v1 mass spec proteomics, aging

68 similar entities Type: Startup Activities: deeptech greentech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission is to focus on the unmet clinical needs of patients suffering from Tenosynovial Giant Cell Tumours (TGCT) SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss

133 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Next-generation protein engineering Proteins are the most advanced nanotechnology we know of. At Adaptyv Bio we’re building a next-gen protein foundry to allow you to synthesize and test any protein you design.

90 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing novel multi-targeted antibiotics with extraordinary potency against multi-drug resistant bacteria. smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

27 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

On-target gene therapies Alia Therapeutics is a pioneering gene editing company with a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomic sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which are required for therapeutic applications.

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Curileum is intervening early in serious gastrointestinal (GI) disease development with novel diagnostics & therapeutics Curileum is intervening early in serious GI disease development with novel therapeutics to detect and correct cell production in the gut mucosa Biotechnology

153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances Aiming to provide improved treatments for chronic respiratory diseases through new, innovative and patent protected substances, thereby reducing suffering and ameliorating quality of life for patients.

380 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unleashing biotech innovation for a greener and fairer future For those creating a more sustainable future with biotechnology, we use AI and computational modelling to help precision fermentation alt protein companies optimise their downstream processing, so they can de-risk their ventures, speed up R&D and reduce costs. Biotechnology, Bioprocessing, Biomanufacturing, Precision Fermetation, ClimateTech, Alternative Protein, Computational Modelling, and Downstream Processing

188 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology

Unlocking the next generation of mRNA medicines. At Sensible Biotechnologies, we are building best-in-class platform for manufacturing of high-quality mRNA in a scalable way to unlock the next generation of mRNA medicines and strengthen the global biosecurity.

109 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing revolutionary biomaterials for regenerative medicine. Spiderwort Inc. is a tissue engineering company specializing in the development of transformative biomaterials for repairing and regenerating tissues within the human body.

60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

An early-stage oncology company aiming to treat solid tumors SOLID Therapeutics is an early-stage oncology company spun out of CBMR at the University of Copenhagen. We are developing novel cancer therapeutics with dual mode of action targeting both cancer cells and immune cells to treat solid tumors.

107 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering CAR Macrophage Immunotherapy to Target Solid Tumors Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA.

42 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing

299 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology